Under a tenth of individuals eligible to benefit from weight-loss injections like Wegovy can access them, states the global health agency as it issues its inaugural advice on the therapies.
Considering more than one billion people worldwide now classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"The new guidance affirms that obesity is a long-term condition that can be managed with thorough and continuous care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to broad availability to the treatments that can aid individuals in losing significant body mass, explains the body.
Even in the present most favorable scenario, the manufacturing of such drugs would only suffice for approximately 100 million people – under 10% of the global need, per the health organization.
The advice urges nations and manufacturers to expand availability, through approaches like voluntary licensing.
Exclusive production rights on a key compound – the primary component of a leading brand – is scheduled to end in several nations in 2026.
The injections mimick a biological compound to reduce digestion speed, suppress the appetite and increase satiety so individuals consume fewer calories.
People typically see weight reduction after several weeks of beginning the regular doses.
Research indicates people may put most of the weight back on within a year of discontinuing the treatment, because their usual hunger resume.
Being carrying excess weight increases your chance for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.